Wang X, Wu N, Yang W R, Shi S S, Ma H H, Wei X, Zhou X J, Rao Q
Department of Pathology, Medicine School of Nanjing University/Nanjing Jinling Hospital, Nanjing 210002, China.
Zhonghua Bing Li Xue Za Zhi. 2016 Jul 8;45(7):457-61. doi: 10.3760/cma.j.issn.0529-5807.2016.07.006.
To study the expression of cadherin17(CDH17) in metanephric adenoma (MA), and to explore the value of CDH17 in the diagnosis of metanephric adenoma.
Immunohistochemical EnVision method was used to detect the expression of CDH17, WT1, CD57, P504S and EMA in 21 cases of MAs, 16 epithelial-predominant Wilms tumors (e-WT), and 20 solid variant of papillary renal cell carcinomas (s-PRCC). The expression of CDH17 was also examined in other common renal epithelial tumors, including 10 cases of clear cell renal cell carcinomas (CCRCC), 10 chromophobe renal cell carcinomas (CHRCC), and 10 oncocytomas.
Twenty (95.2%) of 21 cases of MAs demonstrated membranous CDH17 immunoreactivity in all components (acinar, tubular, and papillary), whereas only 1 (1/16) e-WT was positive for CDH17 and all s-PRCCs were negative (P<0.05). WT1 was negative in s-PRCC and was positive in all cases of e-WT (16/16) and MA (100%, 21/21). All MAs (100%) were strongly positive for CD57; however, this marker was also positive in 13 (13/16) e-WTs and 9 (45.0%, 9/20) s-PRCCs. P504S was strongly positive in all s-PRCCs (100%), but reactivity was seen in 3 (14.3%, 3/21) MAs and all e-WTs were negative. The positive rates of EMA in MAs, e-WTs and s-PRCCs were 19.0%(4/21), 14/16 and 17/20, respectively. The sensitivity and specificity of CDH17 in the diagnosis of MA were 95% and 97%. CDH17 was negative in all cases of CCRCC, CHRCC and oncocytoma.
CDH17 is a highly sensitive and specific marker for MA and should be considered in the immunohistochemistry panel for distinguishing MA from its mimics and other common renal epithelial tumors.
研究钙黏蛋白17（CDH17）在肾母细胞瘤（MA）中的表达情况，并探讨CDH17在肾母细胞瘤诊断中的价值。
采用免疫组织化学EnVision法检测21例MA、16例上皮型为主的肾母细胞瘤（e-WT）及20例实性乳头状肾细胞癌（s-PRCC）中CDH17、WT1、CD57、P504S和EMA的表达。同时检测10例透明细胞肾细胞癌（CCRCC）、10例嫌色细胞肾细胞癌（CHRCC）及10例嗜酸细胞瘤等其他常见肾上皮性肿瘤中CDH17的表达。
21例MA中20例（95.2%）所有成分（腺泡、小管和乳头）均显示CDH17膜性免疫反应性，而16例e-WT中仅1例（1/16）CDH17阳性，所有s-PRCC均为阴性（P<0.05）。WT1在s-PRCC中阴性，在所有e-WT（16/16）和MA（100%，21/21）病例中阳性。所有MA（100%）CD57强阳性；然而，该标志物在13例（13/16）e-WT和9例（45.0%，9/20）s-PRCC中也呈阳性。P504S在所有s-PRCC中均强阳性（100%），但在3例（14.3%，3/21）MA中有反应，所有e-WT均为阴性。MA、e-WT和s-PRCC中EMA的阳性率分别为19.0%（4/21）、14/16和17/20。CDH17诊断MA的敏感性和特异性分别为95%和97%。所有CCRCC、CHRCC和嗜酸细胞瘤病例中CDH17均为阴性。
CDH17是MA的一种高度敏感和特异的标志物，在免疫组织化学鉴别MA与其相似病变及其他常见肾上皮性肿瘤时应予以考虑。
